Breaking Finance News

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been upgraded to Hold in a statement by BidaskClub earlier today.

BidaskClub has upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to Hold in a statement released on 6/20/2017.

Having a price of $119.05, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded 1.44% higher on the day. With the last stock price down 17.59% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. ALXN has recorded a 50-day average of $138.83 and a two hundred day average of $124.75. Trade Volume was up over the average, with 3,713,613 shares of ALXN changing hands over the typical 1,934,280

Recent Performance Chart

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. has PE ratio of 63.61 with a one year low of $96.18 and a one year high of $149.34 and has a market capitalization of $0.

A total of 18 equity analysts have released a ratings update on ALXN. Seven equity analysts rating the company a strong buy, six analysts rating the company a buy, seven analysts rating the company a hold, zero firms rating the stock a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $187.61.

About Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *